SAGE Therapeutics (SAGE) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/15/2026
- Wall St wobbles as rising oil and Treasury yields stoke investor unease
- Oil jumps nearly $3 as Saudi export halt, Libya outages stoke supply fears
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Global AI stocks fall as industry chiefs call for slowing development
- Stocks tend to rise after the Fed starts to hike
- Wall Street ends down, calls for AI slowdown pummel chipmakers
- Explainer-How China is preparing for the risk of AI escaping human control
- Global AI stocks fall as industry chiefs call for slowing development
- Citi sees memory market undersupply worsening through 2031
- Enova drops bid to acquire Grasshopper Bancorp, reaffirms guidance
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Sage Therapeutics Announces Third Quarter 2016 Financial Results and Provides SRSE European Update
November 3, 2016 6:30 AM EDTPositive Scientific Advice From European Medicines Agency on Development of SAGE-547 in SRSE Provides Regulatory Path in E.U.
Ongoing Phase 3 STATUS Trial Expected to be Sufficient to Support a European Marketing Authorization Application for SAGE-547 in SRSE
Eight Clinical Trials Across Pipeline Expected to Generate Top-Line Data in 2017
Moving into Next Strategic Phase - a Multi-Product, Neuropsych Development Portfolio
Conference Call Today at 8:00 AM ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (NASDAQ:... More
